Axela Introduces Assay Kits for Tumor Markers.Tumor Marker Immunoassay Kits first in a series to support biomarker validation. TORONTO -- Axela Inc. has launched nine plate based tumor marker assays. Available in high performance ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent. ELISA n. format they have been designed for stand alone use or to simplify the transition to automated dotLab assays. Used in conjunction with Axela's panelPlus[TM] biomarker menu (available for the dotLab[R] system this summer) this unique approach has the potential to significantly transform the speed with which putative biomarkers can be validated. The following RUO (Research Use Only) immunoassay kits for quantitative determination of cancer antigens are available immediately: alpha-fetoprotein (AFP (1) (AppleTalk Filing Protocol) The file sharing protocol used in an AppleTalk network. In order for non-Apple networks to access data in an AppleShare server, their protocols must translate into the AFP language. See file sharing protocol. ); carcinoembroyonic antigen (CEA CEA carcinoembryonic antigen. CEA abbr. carcinoembryonic antigen CEA (Carcinoembryonic antigen) ); CA125; CA15-3; CA 19-9; PSA (Professional Services Automation) An information system designed to organize, track and manage all opportunities, work, resources, costs, revenues and invoices to improve the productivity and efficiency of the workforce. ; free PSA (f-PSA); free beta subunit of human chorionic gonadotropin human chorionic gonadotropin (HCG): see gonadotropic hormone. (free beta-hCG) and beta-2 Microglobulin (B2MG B2MG Beta 2 Microglobulin ). In order to facilitate assay validation and simplify multiplexing the panelPlus biomarker menu will incorporate the same capture reagents as these ELISA kits. The ability to observe multiple analytes in real-time provides a wider detection range than previously available. Offering significant advantages over end point techniques, the dotLab System allows creation of highly targeted and flexible biomarker panels using these self addressing reagents. Scientists will be able to select from the menu of analytes, and incorporate their own proprietary reagents using the panelPlus address kit. Novel discoveries can be compared directly to markers with known utility without increasing sample volume requirements. Axela is extending the versatility of the dotLab System by providing biomarker assay and validation tools that complement its ability to perform interaction studies, expression monitoring and analysis of cancer autoantibodies. These new, easy to use, robust ELISAs will help researchers quantitate quan·ti·tate tr.v. quan·ti·tat·ed, quan·ti·tat·ing, quan·ti·tates To determine or measure the quantity of. [Back-formation from quantitative (analysis). cancer biomarkers in basic and clinical research settings and will be followed by a selection of cardiology and infectious disease targets. They are available through VWR Life Science in North America and Axela in Europe. To order or for more information, please visit http://www.axela.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion